Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05770895




Registration number
NCT05770895
Ethics application status
Date submitted
1/03/2023
Date registered
16/03/2023
Date last updated
4/04/2024

Titles & IDs
Public title
Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B
Scientific title
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of Repeated Doses of Nonreplicating Arenavirus Vector Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B (CHB)
Secondary ID [1] 0 0
GS-US-642-5670
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Chronic Hepatitis B 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Oral and Gastrointestinal 0 0 0 0
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Other - GS-2829
Treatment: Other - GS-6779
Treatment: Other - Placebo for GS-2829
Treatment: Other - Placebo for GS-6779

Experimental: Cohort 1: GS-2829 Dose A or Placebo - Healthy participants will receive GS-2829 Dose A or placebo for GS-2829.

Experimental: Cohort 2: GS-6779 Dose B or Placebo - Healthy participants will receive GS-6779 Dose B or placebo for GS-6779.

Experimental: Cohort 3: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo - Healthy participants will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.

Experimental: Cohort 4: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo - Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.

Experimental: Cohort 5: GS-2829 Dose A or Placebo + GS-6779 Dose B or Placebo - Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose A or placebo for GS-2829 and GS-6779 Dose B or placebo for GS-6779.

Experimental: Cohort 6: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo - Participants with Chronic Hepatitis B (CHB) who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.

Experimental: Cohort 7: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo - Participants with CHB who are virally suppressed will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.

Experimental: Cohort 8: GS-2829 Dose C or Placebo + GS-6779 Dose D or Placebo - Healthy participants will receive GS-2829 Dose C or placebo for GS-2829 and GS-6779 Dose D or placebo for GS-6779.


Treatment: Other: GS-2829
Administered intramuscularly

Treatment: Other: GS-6779
Administered intramuscularly

Treatment: Other: Placebo for GS-2829
Administered intramuscularly

Treatment: Other: Placebo for GS-6779
Administered intramuscularly
Intervention code [1] 0 0
Treatment: Other
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Treatment-emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Timepoint [1] 0 0
First dose date to end of study followed up to 24 weeks post last dose (Up to Day 225 for Cohorts 1 and 2; Up to Day 309 for Cohorts 3-8)
Primary outcome [2] 0 0
Percentage of Participants With Treatment-emergent Laboratory Abnormalities
Timepoint [2] 0 0
First dose date to end of study followed up to 24 weeks post last dose (Up to Day 225 for Cohorts 1 and 2; Up to Day 309 for Cohorts 3-8)
Secondary outcome [1] 0 0
Proportion of Participants With Vaccine-induced Immune Response
Timepoint [1] 0 0
First dose date to end of study followed up to 24 weeks post last dose (Up to Day 225 for Cohorts 1 and 2; Up to Day 309 for Cohorts 3-8)
Secondary outcome [2] 0 0
Magnitude of Vaccine-Induced Immune Responses as Measured by T-Cell Levels (T-Cell Responses to HBV)
Timepoint [2] 0 0
First dose date to end of study followed up to 24 weeks post last dose (Up to Day 225 for Cohorts 1 and 2; Up to Day 309 for Cohorts 3-8)

Eligibility
Key inclusion criteria
Key

Phase 1a and 1b:

* Body mass index (BMI) of = 32.0 kg/m^2.
* Non-diabetic without impaired glucose tolerance.
* No evidence of cardiac disease based on 12 lead ECG.

Phase 1a (Healthy Individuals) only:

* Aged 18 through 60 years.
* No history of Hepatitis B infection with a negative Hepatitis B virus (HBV) core Antibody.

Phase 1b (Virally suppressed CHB individuals):

* Aged 18 through 65 years.
* Documented CHB and HBsAg = 5000 IU/mL at screening.
* No evidence of advanced fibrosis by Fibroscan (defined as Fibroscan < 9 kPa within 6 months of screening).
* Diagnosed with chronic hepatitis B on suppressive oral antiviral for = 6 months.

Key
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Phase 1a and 1b:

* Use of any systemic antibiotics within 30 days of screening.
* Receipt of any HBV vaccine within 12 months of screening visit or planning HBV vaccination during the study period.
* Receipt of any investigational product within 3 months or vaccine within 3 months of screening (with the exception of influenza and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, which if needed, should be administered at least 14 days before or after an investigational product administration).
* Receipt of immunoglobulin or other blood products within 3 months of screening.
* Positive serum pregnancy test at screening or positive urine pregnancy on Day 1.
* Have been treated with systemic steroids, immunosuppressant therapies, or chemotherapeutic agents within 3 months prior to screening or is expected to receive these agents during the study (eg, corticosteroids, immunoglobulins, other immune or cytokine-based therapies).
* Participation in any other clinical study (including observational studies) without prior approval from the sponsor is prohibited while participating in the study.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
3/04/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/01/2025
Actual
Sample size
Target
Accrual to date
Final
83
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
New Zealand
State/province [1] 0 0
Auckland
Country [2] 0 0
Taiwan
State/province [2] 0 0
Chiayi City
Country [3] 0 0
Taiwan
State/province [3] 0 0
Kaohsiung City
Country [4] 0 0
Taiwan
State/province [4] 0 0
Kaohsiung
Country [5] 0 0
Taiwan
State/province [5] 0 0
Tainan City
Country [6] 0 0
Taiwan
State/province [6] 0 0
Taipei City
Country [7] 0 0
Taiwan
State/province [7] 0 0
Taoyuan City

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Gilead Sciences
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The goal of this clinical study is to learn more about GS-2829 and GS-6779 in healthy participants and participants with CHB.
Trial website
https://clinicaltrials.gov/study/NCT05770895
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gilead Study Director
Address 0 0
Gilead Sciences
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05770895